Pivotal Group, a Phoenix-based private investment firm, has announced its acquisition of Precision Science, an animal health contract manufacturer. This marks Pivotal Group’s first investment in the animal health sector, focusing on pharmaceuticals, medicated feed additives, and nutritional supplements.
The acquisition will create a new manufacturing platform for animal health within Pivotal Group, which plans to enhance production capacity, invest in technology, and bolster Precision Science’s research and development efforts. Financial terms of the transaction were not disclosed.
Established in 1989, Precision Science offers contract manufacturing and product development services to global animal health companies and other businesses in the veterinary and animal care markets. The company produces a diverse range of animal health products, including pharmaceutical formulations and nutritional supplements.
Pivotal Group identified Precision Science as a strategic opportunity to build a larger manufacturing operation in the expanding animal health market. “The acquisition of Precision Science represents an exciting opportunity for Pivotal Group to build a leading platform focused on animal health starting with supplements and pharmaceuticals,” said Francis Najafi, the founder and CEO of Pivotal Group.
Najafi indicated that Pivotal Group will provide the necessary capital and resources for operational enhancements, technological development, and workforce support. Following the acquisition, Pivotal Group has allocated additional funds to increase Precision Science’s manufacturing capacity and upgrade its technological infrastructure.
A key element of this expansion is a new 130,000-square-foot automated manufacturing facility currently under construction in North Phoenix. Approximately two-thirds complete, this facility aims to substantially elevate Precision Science’s production capabilities and prepare for future growth.
The new site will incorporate three additional production lines and enable the manufacture of liquid formulations, alongside existing pharmaceutical and supplement operations. It will also enhance analytical testing, product development, and logistics capabilities.
Bryan Vincent, CEO of Precision Science, expressed optimism about the acquisition, noting it will provide essential resources for the company’s forthcoming development phase. “Our clients are asking us to look ahead—to anticipate where animal health is going and invest in the capabilities that will help them get there,” he said. He emphasized that the investment will support workforce development and advanced product research.
As it expands, Precision Science remains committed to maintaining quality, product safety, and regulatory compliance across its operations. The company operates out of an FDA-registered facility reinforced by an in-house laboratory and robust quality management systems.
The expansion is anticipated to generate additional job opportunities in the Phoenix area for production, technical, and leadership roles. The acquisition signifies a diversification of Pivotal Group’s investment portfolio, extending into animal health and pharmaceutical contract manufacturing.
Pivotal Group, founded by Francis Najafi, previously invested in technology companies, including Network Solutions and MegaPath. The acquisition of Precision Science provides Pivotal Group with a platform in the animal health sector, where contract manufacturers play a crucial role in assisting pharmaceutical companies and supplement brands.
Details regarding the acquisition price, Precision Science’s annual revenue, employee count, and the completion date for the new facility have not been disclosed.


